Table 2 Clinicopathologic characteristics between breast cancer patients with/without bone metastasis
From: Clinicomics-guided distant metastasis prediction in breast cancer via artificial intelligence
Character | Training set | Â | Â | Validation set | ||
|---|---|---|---|---|---|---|
Distant metastasis | HR (95% CI) | P-value | Distant metastasis | |||
no | yes | no | yes | |||
Age (mean ± SD, years) | 46.8 (9.75) | 47.1 (12.3) | 1 (0.964–1.05) | 0.847 | 49.6 (9.27) | 45.6 (7.82) |
Family history of BC | ||||||
 Yes | 5 (5.75) | 0 (0.00) |  < 0.001 (0-Inf) | 0.997 | 1 (2.70%) | 1 (10.00%) |
 No | 82 (94.25) | 23 (100.00) | 36 (97.30%) | 9 (90.00%) | ||
Breast-feeding histories | ||||||
 Yes | 76 (87.36) | 18 (78,326) | 0.579 (0.215–1.56) | 0.279 | 32 (86.49%) | 8 (80.00%) |
 No | 11 (12.64) | 5 (21.74) | 5 (13.51%) | 2 (20.00%) | ||
Abortion | ||||||
 Yes | 52 (59.77) | 11 (47.83) | 0.622 (0.274–1.41) | 0.255 | 24 (64.86%) | 6 (60.00%) |
 No | 35 (40.23) | 12 (52.17) | 13 (35.14%) | 4 (40.00%) | ||
Reproductive history | ||||||
 Yes | 83 (95.40) | 19 (82.61) | 0.314 (0.107–0.926) | 0.036 | 35 (94.59%) | 9 (90.00%) |
 No | 4 (4.60) | 4 (17.39) | 2 (5.41%) | 1 (10.00%) | ||
Menstrual status | ||||||
 Menstruate | 57 (65.52) | 15 (65.22) | 1.05 (0.446–2.48) | 0.908 | 21 (56.76%) | 7 (70.00%) |
 Menopause | 30 (34.48) | 8 (34.78) | 16 (43.24%) | 3 (30.00%) | ||
Age of menarche | 14.1 (1.73) | 14.6 (1.73) | 1.04 (0.82–1.32) | 0.741 | 14.7 (1.73) | 14.2 (2.66) |
Lymph node metastasis | ||||||
 Have | 19 (21.84) | 14 (60.87) | 4.76 (2.06–11) |  < 0.001 | 11 (29.73%) | 7 (70.00%) |
 None | 68 (78.16) | 9 (39.13) | 26 (70.27%) | 3 (30.00%) | ||
molecular subtyping | ||||||
 1 | 9 (10.34) | 4 (17.39) | 0.738 (0.419–1.3) | 0.293 | 4 (10.81%) | 0 (0.00%) |
 2 | 61 (70.11) | 16 (69.57) | 24 (64.86%) | 7 (70.00%) | ||
 3 | 4 (4.60) | 1 (4.35) | 2 (5.41%) | 1 (10.00%) | ||
 4 | 13 (14.94) | 2 (8.70) | 7 (18.92%) | 2 (20.00%) | ||
ER | ||||||
 Positive | 70 (80.46) | 19 (82.61) | 1.2 (0.407–3.52) | 0.743 | 28 (75.68%) | 7 (70.00%) |
 Negative | 17 (19.54) | 4 (17.39) | 9 (24.32%) | 3 (30.00%) | ||
PR | ||||||
 Positive | 68 (78.16) | 20 (86.96) | 1.8 (0.535–6.06) | 0.343 | 27 (72.97%) | 4 (40.00%) |
 Negative | 19 (21.84) | 3 (13.04) | 10 (27.03%) | 6 (60.00%) | ||
HER2 status | ||||||
 Positive | 57 | 15 | 0.931 (0.528–1.64) | 0.805 | 27 | 6 |
 Negative | 30 | 8 | 10 | 4 | ||
Ki-67 | ||||||
 Positive | 76 (87.36) | 20 (86.96) | 1 (0.983–1.02) | 0.985 | 33 (89.19%) | 9 (90.00%) |
 Negative | 11 (12.64) | 3 (13.04) | 4 (10.81%) | 1 (10.00%) | ||
TPSA | ||||||
 Positive | 9 (10.34) | 5 (21.74) | 2.13 (0.788–5.73) | 0.136 | 4 (10.81%) | 1 (10.00%) |
 Negative | 78 (89.66) | 18 (78.26) | 33 (89.19%) | 9 (90.00%) | ||
CA153 | ||||||
 Positive | 1 (1.15) | 7 (30.43) | 13.4 (5.27–33.8) |  < 0.001 | 0 (0.00%) | 1 (10.00%) |
 Negative | 86 (98.85) | 16 (69.57) | 37 (100.00%) | 9 (90.00%) | ||
CEA | ||||||
 Positive | 0 (0.00) | 4 (17.) | 39.9 (10.7–149) |  < 0.001 | 1 (2.70%) | 2 (20.00%) |
 Negative | 87 (100.00) | 19 (82.61) | 36 (97.30%) | 8 (80.00%) | ||
CA125 | ||||||
 Positive | 3 (3.45) | 4 (17.39) | 4.37 (1.48–12.9) | 0.008 | 5 (13.51%) | 2 (20.00%) |
 Negative | 84 (96.55) | 19 (82.61) | 32 (86.49%) | 8 (80.00%) | ||
Operation | ||||||
 No surgery | 0 (0.00) | 3 (13.04) | 0.597 (0.282–1.26) | 0.178 | 0 (0.00%) | 3 (30.00%) |
 Conserving | 39 (44.83) | 8 (34.78) | 16 (43.24%) | 2 (20.00%) | ||
 Radical | 48 (55.17) | 12 (52.17) | 21 (56.76%) | 5 (50.00%) | ||
Endocrinotherapy | ||||||
 Yes | 10 (11.49) | 0 (0.00) | 1.28e-08 (0-Inf) | 0.997 | 2 (5.41%) | 0 (0.00%) |
 No | 77 (88.51) | 23 (100.00) | 35 (94.59%) | 10 (100.00% | ||
Radiotherapy | ||||||
 Yes | 12 (13.79) | 6 (26.09) | 0.105 | 0.159 | 5 (13.51%) | 5 (50.00%) |
 No | 75 (86.21) | 17 (73.91) | 32 (86.49%) | 5 (50.00%) | ||
Chemotherapy | ||||||
 Yes | 80 (91.95) | 23 (100.00) | 1.91 (0.754–4.86) | 0.172 | 33 (89.19%) | 10 (100.00%) |
 No | 7 (8.05) | 0 (0.00) | 4 (10.81%) | 0 (0.00%) | ||
RadScore (mean ± SD) | -2.77 (0.56) | -1.72 (0.43) | 15.9 (6.43–39.5) |  < 0.001 | -2.60 (0.67) | -2.40 (0.71) |